Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.

CONCLUSIONS: These data support a "first in RDEB" phase II clinical trial of rigosertib to assess tumor targeting in patients with late stage, metastatic and/ or unresectable SCC.
PMID: 30846478 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - March 6, 2019 Category: Cancer & Oncology Authors: Atanasova VS, Pourreyron C, Farshchian M, Lawler ME, Brown CA, Watt S, Wright S, Warkala M, Guttmann-Gruber C, Pinon-Hofbauer J, Fuentes I, Prisco M, Rashidghamat E, Has C, Salas-Alanis JC, Palisson F, Hovnanian A, McGrath JA, Mellerio J, Bauer JW, South Tags: Clin Cancer Res Source Type: research